AbbVie Inc. (ABBV) FY2024 YTD Q3 Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2024-01-01 to 2024-09-30

Swipe to see the full flow
AbbVie Inc. cash flow reconciliation, Jan 1, 2024 through Sep 30, 2024One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net earnings → Net cash from operating activities: $4,309,000,000.00Amortization of intangible assets → Operating adjustments reconciliation: $5,726,000,000.00Change in fair value of contingent consideration liabilities → Operating adjustments reconciliation: $3,492,000,000.00Acquired IPR&D and milestones → Operating adjustments reconciliation: $1,183,000,000.00Stock-based compensation → Operating adjustments reconciliation: $747,000,000.00Depreciation → Operating adjustments reconciliation: $558,000,000.00Prepaid expenses and other assets → Operating adjustments reconciliation: $461,000,000.00Non-cash litigation reserve adjustments, net of cash payments → Operating adjustments reconciliation: $341,000,000.00Operating adjustments reconciliation → Net cash from operating activities: $7,449,000,000.00Operating adjustments reconciliation → Payment for Contingent Consideration Liability, Operating Activities: $1,456,000,000.00Operating adjustments reconciliation → Income tax assets and liabilities, net: $1,405,000,000.00Operating adjustments reconciliation → Accounts payable and other liabilities: $1,070,000,000.00Operating adjustments reconciliation → Deferred income taxes: $682,000,000.00Operating adjustments reconciliation → Inventories: $191,000,000.00Operating adjustments reconciliation → Accounts receivable: $180,000,000.00Operating adjustments reconciliation → Other, net: $75,000,000.00Proceeds from issuance of long-term debt → financing reconciliation: $14,963,000,000.00Proceeds from Short-Term Debt → financing reconciliation: $5,008,000,000.00Proceeds from the exercise of stock options → financing reconciliation: $204,000,000.00Other, net → financing reconciliation: $56,000,000.00financing reconciliation → Net cash from financing activities: $1,650,000,000.00financing reconciliation → Dividends paid: $8,273,000,000.00financing reconciliation → Repayments of other short-term borrowings: $5,008,000,000.00financing reconciliation → Repayments of long-term debt and finance lease obligations: $3,851,000,000.00financing reconciliation → Purchases of treasury stock: $1,350,000,000.00financing reconciliation → Payments of Debt Issuance Costs: $99,000,000.00Net cash used in investing activities → investing reconciliation: $18,946,000,000.00Sales and maturities of investment securities → investing reconciliation: $516,000,000.00investing reconciliation → Payments to Acquire Businesses, Net of Cash Acquired: $17,493,000,000.00investing reconciliation → Other acquisitions and investments: $1,232,000,000.00investing reconciliation → Acquisitions of property and equipment: $683,000,000.00investing reconciliation → Purchases of investment securities: $46,000,000.00investing reconciliation → Other, net: $8,000,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $12,814,000,000.00Net cash from operating activities → Cash sources and uses: $11,758,000,000.00Net cash from financing activities → Cash sources and uses: $1,650,000,000.00Cash sources and uses → Exchange-rate effect: $19,000,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $7,257,000,000.00Cash sources and uses → Net cash used in investing activities: $18,946,000,000.00Change in fair value of contingent consideration liabilities: $3,492,000,000.00Contingent consideration change+$3.49 BAmortization of intangible assets: $5,726,000,000.00Intangible amortization+$5.73 BAcquired IPR&D and milestones: $1,183,000,000.00Acquired IPR&D written off+$1.18 BAccounts payable and other liabilities: -$1,070,000,000.00Payables & accrued liabilities−$1.07 BPrepaid expenses and other assets: $461,000,000.00Prepaid & other assets+$461.00 MImpairment of intangible assets: $0.00Other, net: -$75,000,000.00Other non-cash items−$75.00 MStock-based compensation: $747,000,000.00Stock-based compensation+$747.00 MInventories: -$191,000,000.00Inventories−$191.00 MIncome tax assets and liabilities, net: -$1,405,000,000.00Income taxes, net−$1.41 BNet earnings: $4,309,000,000.00Net earnings+$4.31 BDepreciation: $558,000,000.00Depreciation expense+$558.00 MDeferred income taxes: -$682,000,000.00Deferred income taxes−$682.00 MAccounts receivable: -$180,000,000.00Accounts receivable−$180.00 MPayment for Contingent Consideration Liability, Operating Activities: -$1,456,000,000.00Contingent consideration paid−$1.46 BNon-cash litigation reserve adjustments, net of cash payments: $341,000,000.00Non-cash litigation, net+$341.00 MNet cash from operating activities: $11,758,000,000.00Operating cash+$11.76 BOperating adjustments reconciliation: $12,508,000,000.00Payments of Debt Issuance Costs: -$99,000,000.00Debt issuance costs−$99.00 MDividends paid: -$8,273,000,000.00Dividends paid−$8.27 BPurchases of treasury stock: -$1,350,000,000.00Common stock repurchases−$1.35 BRepayments of other short-term borrowings: -$5,008,000,000.00Other short-term debt repaid−$5.01 BProceeds from the exercise of stock options: $204,000,000.00Stock option exercises+$204.00 MPayments of contingent consideration liabilities: $0.00Other, net: $56,000,000.00Other financing, net+$56.00 MProceeds from Short-Term Debt: $5,008,000,000.00Short-term debt issued+$5.01 BRepayments of long-term debt and finance lease obligations: -$3,851,000,000.00Debt & capital securities repaid−$3.85 BProceeds from issuance of long-term debt: $14,963,000,000.00Long-term debt issued+$14.96 BNet cash from financing activities: $1,650,000,000.00Financing cash+$1.65 Bfinancing reconciliation: $20,231,000,000.00Acquisitions of property and equipment: -$683,000,000.00PP&E purchases−$683.00 MPurchases of investment securities: -$46,000,000.00Marketable securities purchases−$46.00 MOther acquisitions and investments: -$1,232,000,000.00Other investment purchases−$1.23 BOther, net: -$8,000,000.00Other investing, net−$8.00 MSales and maturities of investment securities: $516,000,000.00Investment sales & maturities+$516.00 MPayments to Acquire Businesses, Net of Cash Acquired: -$17,493,000,000.00Acquisitions, net of cash−$17.49 BNet cash used in investing activities: -$18,946,000,000.00. Cash required to fund net payments.Investing cash−$18.95 Binvesting reconciliation: $19,462,000,000.00Cash sources and uses: $26,222,000,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $12,814,000,000.00Beginning cash$12.81 BEnding cash: Cash, cash equivalents, and restricted cash: $7,257,000,000.00Ending cash$7.26 BExchange-rate effect: -$19,000,000.00FX effect−$19.00 MCASH RECONCILIATIONOperatingflowsFinancingflowsInvestingflowsFree cash flow$11.08 BOperating cash − cash spent on PP&ECash flow / Net income2.73×Operating cash flow ÷ net incomeNet cash change−$5.56 BEnding cash − beginning cash
Chart details

AbbVie Inc. cash flow reconciliation, Jan 1, 2024 through Sep 30, 2024

Cash flows for Jan 1, 2024 through Sep 30, 2024. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2023. Ending cash: Sep 30, 2024. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2023
12,814,000,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
11,758,000,000 US dollars. Net cash provided.
Change in fair value of contingent consideration liabilities
3,492,000,000 US dollars
Amortization of intangible assets
5,726,000,000 US dollars
Acquired IPR&D and milestones
1,183,000,000 US dollars
Accounts payable and other liabilities
negative 1,070,000,000 US dollars
Prepaid expenses and other assets
461,000,000 US dollars
Impairment of intangible assets
0 US dollars
Other, net
negative 75,000,000 US dollars
Stock-based compensation
747,000,000 US dollars
Inventories
negative 191,000,000 US dollars
Income tax assets and liabilities, net
negative 1,405,000,000 US dollars
Net earnings
4,309,000,000 US dollars
Depreciation
558,000,000 US dollars
Deferred income taxes
negative 682,000,000 US dollars
Accounts receivable
negative 180,000,000 US dollars
Payment for Contingent Consideration Liability, Operating Activities
negative 1,456,000,000 US dollars
Non-cash litigation reserve adjustments, net of cash payments
341,000,000 US dollars
Investing activities
negative 18,946,000,000 US dollars. Net cash used.
Acquisitions of property and equipment
negative 683,000,000 US dollars
Purchases of investment securities
negative 46,000,000 US dollars
Other acquisitions and investments
negative 1,232,000,000 US dollars
Other, net
negative 8,000,000 US dollars
Sales and maturities of investment securities
516,000,000 US dollars
Payments to Acquire Businesses, Net of Cash Acquired
negative 17,493,000,000 US dollars
Financing activities
1,650,000,000 US dollars. Net cash provided.
Payments of Debt Issuance Costs
negative 99,000,000 US dollars
Dividends paid
negative 8,273,000,000 US dollars
Purchases of treasury stock
negative 1,350,000,000 US dollars
Repayments of other short-term borrowings
negative 5,008,000,000 US dollars
Proceeds from the exercise of stock options
204,000,000 US dollars
Payments of contingent consideration liabilities
0 US dollars
Other, net
56,000,000 US dollars
Proceeds from Short-Term Debt
5,008,000,000 US dollars
Repayments of long-term debt and finance lease obligations
negative 3,851,000,000 US dollars
Proceeds from issuance of long-term debt
14,963,000,000 US dollars
Operating adjustment reconciliation
12,508,000,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
20,231,000,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
19,462,000,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
negative 19,000,000 US dollars
Ending cash on Sep 30, 2024
7,257,000,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
26,222,000,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 5,557,000,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
2.73×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
11,758,000,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
683,000,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
11,075,000,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income enters operating cash directly in the reconciliation. The adjustment junction contributes the remaining $7.45B after reconciling the other positive and negative adjustments. These connections depict an accounting reconciliation, not traced cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 11,758,000,000 US dollars minus 683,000,000 US dollars equals 11,075,000,000 US dollars.
AbbVie Inc. (ABBV) FY2024 YTD Q3 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!